Sunnymeath Asset Management Inc. continued to hold its position in shares of Merck & Co. (NYSE:MRK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,810 shares of the company’s stock at the end of the second quarter. Sunnymeath Asset Management Inc.’s holdings in Merck & Co. were worth $105,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of MRK. Murphy Capital Management Inc. raised its position in shares of Merck & Co. by 3.1% in the second quarter. Murphy Capital Management Inc. now owns 47,161 shares of the company’s stock worth $2,716,000 after buying an additional 1,429 shares during the period. State of Alaska Department of Revenue acquired a new position in shares of Merck & Co. during the second quarter worth about $1,816,000. Nordea Investment Management AB raised its position in shares of Merck & Co. by 16.1% in the second quarter. Nordea Investment Management AB now owns 2,411,985 shares of the company’s stock worth $138,954,000 after buying an additional 334,806 shares during the period. Capital One National Association raised its position in shares of Merck & Co. by 4.4% in the second quarter. Capital One National Association now owns 108,338 shares of the company’s stock worth $6,241,000 after buying an additional 4,576 shares during the period. Finally, Telemus Capital LLC raised its position in shares of Merck & Co. by 2.2% in the second quarter. Telemus Capital LLC now owns 34,145 shares of the company’s stock worth $1,967,000 after buying an additional 727 shares during the period. 72.94% of the stock is owned by institutional investors and hedge funds.

Merck & Co. (NYSE:MRK) traded down 0.16% during trading on Friday, reaching $62.28. 12,432,293 shares of the company’s stock traded hands. The firm has a market cap of $172.22 billion, a PE ratio of 34.16 and a beta of 0.63. The firm has a 50 day moving average price of $61.95 and a 200-day moving average price of $57.17. Merck & Co. has a 12 month low of $47.97 and a 12 month high of $64.00.

Merck & Co. (NYSE:MRK) last announced its quarterly earnings data on Friday, July 29th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.91 by $0.02. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The firm had revenue of $9.84 billion for the quarter, compared to analysts’ expectations of $9.79 billion. During the same period last year, the firm earned $0.86 earnings per share. The business’s revenue for the quarter was up .6% on a year-over-year basis. On average, analysts forecast that Merck & Co. will post $3.75 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be paid a $0.46 dividend. The ex-dividend date of this dividend is Tuesday, September 13th. This represents a $1.84 dividend on an annualized basis and a yield of 2.95%. Merck & Co.’s payout ratio is presently 101.10%.

A number of equities analysts recently issued reports on the company. Argus reissued a “buy” rating and issued a $65.00 price objective on shares of Merck & Co. in a report on Wednesday. Morgan Stanley set a $60.00 target price on Merck & Co. and gave the stock a “hold” rating in a research report on Tuesday, September 13th. Jefferies Group restated a “hold” rating and issued a $56.00 target price (down from $57.00) on shares of Merck & Co. in a research report on Monday, September 12th. Berenberg Bank restated a “hold” rating and issued a $62.00 target price on shares of Merck & Co. in a research report on Sunday, September 11th. Finally, Barclays PLC upped their target price on Merck & Co. from $66.00 to $72.00 and gave the stock an “overweight” rating in a research report on Friday, September 9th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of €63.31 ($70.34).

In other news, CEO Kenneth C. Frazier sold 60,000 shares of Merck & Co. stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of €58.00 ($64.44), for a total transaction of €3,480,000.00 ($3,866,666.67). Following the transaction, the chief executive officer now directly owns 554,856 shares of the company’s stock, valued at €32,181,648 ($35,757,386.67). The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Adam H. Schechter sold 39,200 shares of Merck & Co. stock in a transaction on Thursday, September 1st. The stock was sold at an average price of €62.61 ($69.57), for a total transaction of €2,454,312.00 ($2,727,013.33). Following the transaction, the executive vice president now directly owns 39,200 shares in the company, valued at €2,454,312 ($2,727,013.33). The disclosure for this sale can be found here. 0.05% of the stock is currently owned by company insiders.

About Merck & Co.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

5 Day Chart for NYSE:MRK

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.